Business Development

Challenge: A pharma company was interested in identifying novel protein-based autoimmune / auto-inflammatory assets early in development from pre-GLP studies to 18 months from an IND. The company had...

Challenge: A phase 2 clinical-stage pharma company intent on supplementing their internal pipeline with external innovation asked Alacrita to identify immune-oncology or vaccine assets owned by...

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...

Challenge A European investor required due diligence on a lead preclinical candidate being developed by a biotech company for the treatment and prevention of aortic valve stenosis (AVS). Alacrita was...

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...